Aldeyra Therapeutics
Aldeyra Therapeutics
ALDX
NASDAQ
6.91
USD
1.47%
About
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases.
Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome.
Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 362.5K |
| Three Month Average Volume | 9.8M |
| High Low | |
| Fifty-Two Week High | 7.66 USD |
| Fifty-Two Week Low | 1.42 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 16 Oct 2023 |
| Price and Volume | |
| Current Price | 5.755 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 54.98% |
| Thirteen Week Relative Price Change | 39.30% |
| Twenty-Six Week Relative Price Change | 24.03% |
| Fifty-Two Week Relative Price Change | -38.44% |
| Year-to-Date Relative Price Change | 38.46% |
| Price Change | |
| One Day Price Change | 7.07% |
| Thirteen Week Price Change | 49.09% |
| Twenty-Six Week Price Change | 36.37% |
| Five Day Price Change | 3.32% |
| Fifty-Two Week Price Change | -22.86% |
| Year-to-Date Price Change | 63.96% |
| Month-to-Date Price Change | 46.07% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.0237 USD |
| Book Value Per Share (Most Recent Quarter) | 1.65465 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.0237 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.65465 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.72225 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.63693 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.63866 USD |
| Normalized (Last Fiscal Year) | -0.63693 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.63693 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.63866 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.63693 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.63866 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.41272 USD |
| Cash Per Share (Most Recent Quarter) | 2.02529 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.63247 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.63482 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.51847 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -9.32% |
| Tangible Book Value (5 Year) | 6.70% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -85.50% |
| EPS Change (Trailing Twelve Months) | 28.06% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -105,089,300 |
| Net Debt (Last Fiscal Year) | -127,676,500 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -30,326,130 |
| Free Cash Flow (Trailing Twelve Months) | -30,721,470 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 13 |
| Total Debt to Equity (Most Recent Quarter) | 16 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -22.78% |
| Return on Assets (Trailing Twelve Months) | -26.89% |
| Return on Assets (5 Year) | -36.79% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -27.73% |
| Return on Equity (Trailing Twelve Months) | -33.19% |
| Return on Equity (5 Year) | -45.06% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -25.71% |
| Return on Investment (Trailing Twelve Months) | -31.76% |
| Return on Investment (5 Year) | -40.77% |